Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription Articles published in Lancet Oncol Retrieve available abstracts of 93 articles: HTML format

Single Articles

April 2024
1. VAN DER VOORT A, Louis FM, van Ramshorst MS, Kessels R, et al
   MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
   Lancet Oncol. 2024 Apr 5:S1470-2045(24)00104.
   PubMed     Abstract available
   
   
   
2. BROWNE IM, Andre F, Chandarlapaty S, Carey LA, et al
   Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.
   Lancet Oncol. 2024;25:e139-e151.
   PubMed     Abstract available
   
   
   
3. LAYMAN RM, Han HS, Rugo HS, Stringer-Reasor EM, et al
   Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
   Lancet Oncol. 2024;25:474-487.
   PubMed     Abstract available
   
   
   March 2024
4. TOI M, Kinoshita T, Benson JR, Jatoi I, et al
   Non-surgical ablation for breast cancer: an emerging therapeutic option.
   Lancet Oncol. 2024;25:e114-e125.
   PubMed     Abstract available
   
   
   February 2024
5. PALMIERI C, Linden H, Birrell SN, Wheelwright S, et al
   Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multin
   Lancet Oncol. 2024 Feb 8:S1470-2045(24)00004.
   PubMed     Abstract available
   
   
   
6. CHEN N, Nanda R
   Androgen receptor agonism in advanced oestrogen receptor-positive breast cancer.
   Lancet Oncol. 2024 Feb 8:S1470-2045(24)00080.
   PubMed    
   
   
   
7. MEATTINI I, Becherini C, Caini S, Coles CE, et al
   International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations.
   Lancet Oncol. 2024;25:e73-e83.
   PubMed     Abstract available
   
   
   
8. BAJPAI J, Kapu V, Rath S, Kumar S, et al
   Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled,
   Lancet Oncol. 2024;25:246-254.
   PubMed     Abstract available
   
   
   January 2024
9. OKINES A, Turner N
   Developing therapies for triple-negative breast cancer subtypes.
   Lancet Oncol. 2024 Jan 8:S1470-2045(23)00639.
   PubMed    
   
   
   
10. FAN L, Wang ZH, Ma LX, Wu SY, et al
    Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
    Lancet Oncol. 2024 Jan 8:S1470-2045(23)00579.
    PubMed     Abstract available
    
    
    
11. CHUMSRI S
    Serum hormone concentrations and individualisation of breast cancer prevention.
    Lancet Oncol. 2024;25:8-9.
    PubMed    
    
    
    December 2023
12. THE EDITORS OF THE LANCET ONCO
    Expression of concern-Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
    Lancet Oncol. 2023 Dec 21:S1470-2045(23)00673.
    PubMed    
    
    
    
13. CUZICK J, Chu K, Keevil B, Brentnall AR, et al
    Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial.
    Lancet Oncol. 2023 Dec 5:S1470-2045(23)00578.
    PubMed     Abstract available
    
    
    
14. THE LANCET ONCOLOGY
    Breast cancer screening: one size does not fit all.
    Lancet Oncol. 2023;24:1287.
    PubMed    
    
    
    November 2023
15. VELIKOVA G, Morden JP, Haviland JS, Emery C, et al
    Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomis
    Lancet Oncol. 2023 Nov 2:S1470-2045(23)00460.
    PubMed     Abstract available
    
    
    
16. HORINO T
    Retroperitoneal metastasis of breast cancer misdiagnosed as retroperitoneal fibrosis.
    Lancet Oncol. 2023;24:e451.
    PubMed    
    
    
    September 2023
17. XU B
    Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy - Author's reply.
    Lancet Oncol. 2023;24:e357.
    PubMed    
    
    
    
18. HINDIE E
    Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy.
    Lancet Oncol. 2023;24:e356.
    PubMed    
    
    
    
19. TOI M, Aruga T
    SERDs for primary breast cancer.
    Lancet Oncol. 2023;24:947-949.
    PubMed    
    
    
    
20. HURVITZ SA, Bardia A, Quiroga V, Park YH, et al
    Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
    Lancet Oncol. 2023;24:1029-1041.
    PubMed     Abstract available
    
    
    August 2023
21. PASQUIER D, Bidaut L, Oprea-Lager DE, deSouza NM, et al
    Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups.
    Lancet Oncol. 2023;24:e331-e343.
    PubMed     Abstract available
    
    
    
22. LANG K, Josefsson V, Larsson AM, Larsson S, et al
    Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening
    Lancet Oncol. 2023;24:936-944.
    PubMed     Abstract available
    
    
    
23. SEGNAN N, Ponti A
    Artificial intelligence for breast cancer screening: breathtaking results and a word of caution.
    Lancet Oncol. 2023;24:830-832.
    PubMed    
    
    
    June 2023
24. CHEN X, Shen K
    Dalpiciclib in advanced breast cancer.
    Lancet Oncol. 2023;24:578-579.
    PubMed    
    
    
    
25. HUNTLEY C, Torr B, Sud A, Rowlands CF, et al
    Utility of polygenic risk scores in UK cancer screening: a modelling analysis.
    Lancet Oncol. 2023;24:658-668.
    PubMed     Abstract available
    
    
    May 2023
26. VENKATESAN P
    New US breast cancer screening recommendations.
    Lancet Oncol. 2023 May 18:S1470-2045(23)00238.
    PubMed    
    
    
    
27. ZHANG P, Zhang Q, Tong Z, Sun T, et al
    Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo
    Lancet Oncol. 2023 May 11:S1470-2045(23)00172.
    PubMed     Abstract available
    
    
    
28. MEIRSON T, Goldstein DA, Gyawali B, Tannock IF, et al
    Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer.
    Lancet Oncol. 2023 May 2:S1470-2045(23)00165.
    PubMed    
    
    
    
29. JOHNSTON SRD, Tolaney SM, O'Shaughnessy J, Rastogi P, et al
    Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer - Authors' reply.
    Lancet Oncol. 2023 May 2:S1470-2045(23)00214.
    PubMed    
    
    
    April 2023
30. BEHROOZIAN T, Bonomo P, Patel P, Kanee L, et al
    Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recommendations.
    Lancet Oncol. 2023;24:e172-e185.
    PubMed     Abstract available
    
    
    March 2023
31. WU S, Hong G, Xu A, Zeng H, et al
    Artificial intelligence-based model for lymph node metastases detection on whole slide images in bladder cancer: a retrospective, multicentre, diagnostic study.
    Lancet Oncol. 2023 Mar 6:S1470-2045(23)00061.
    PubMed     Abstract available
    
    
    
32. JOHNSTON SRD, Andre V
    Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer - Authors' reply.
    Lancet Oncol. 2023;24:e104.
    PubMed    
    
    
    
33. NOZAWA K, Sawaki M, Iwata H
    Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer.
    Lancet Oncol. 2023;24:e103.
    PubMed    
    
    
    
34. TOLANEY SM, Tarantino P, Graham N, Tayob N, et al
    Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
    Lancet Oncol. 2023;24:273-285.
    PubMed     Abstract available
    
    
    
35. GEUNA E, Curigliano G, Montemurro F
    De-escalation in low-risk, HER2-positive breast cancer.
    Lancet Oncol. 2023;24:200-201.
    PubMed    
    
    
    February 2023
36. CHATTERJI S, Krzoska E, Thoroughgood CW, Saganty J, et al
    Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review.
    Lancet Oncol. 2023;24:e74-e85.
    PubMed     Abstract available
    
    
    
37. STRNAD V, Polgar C, Ott OJ, Hildebrandt G, et al
    Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial.
    Lancet Oncol. 2023 Feb 1:S1470-2045(23)00018.
    PubMed     Abstract available
    
    
    January 2023
38. RODLER E, Sharma P, Barlow WE, Gralow JR, et al
    Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet Oncol. 2023 Jan 6:S1470-2045(22)00739.
    PubMed     Abstract available
    
    
    
39. HU X, Fujiwara T, Sun Y, Huang W, et al
    Treatment-related thoracic soft tissue sarcomas in survivors of breast cancer.
    Lancet Oncol. 2023;24:e6.
    PubMed    
    
    
    
40. GARCIA-PELAEZ J, Barbosa-Matos R, Lobo S, Dias A, et al
    Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes.
    Lancet Oncol. 2023;24:91-106.
    PubMed     Abstract available
    
    
    December 2022
41. JOHNSTON SRD, Toi M, O'Shaughnessy J, Rastogi P, et al
    Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
    Lancet Oncol. 2022 Dec 5:S1470-2045(22)00694.
    PubMed     Abstract available
    
    
    
42. SPANHEIMER PM, Reeder-Hayes KE
    Breast surgery after neoadjuvant chemotherapy: time for a change?
    Lancet Oncol. 2022;23:1477-1479.
    PubMed    
    
    
    November 2022
43. DEL MASTRO L, Poggio F, Blondeaux E, De Placido S, et al
    Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
    Lancet Oncol. 2022 Nov 9. pii: S1470-2045(22)00632.
    PubMed     Abstract available
    
    
    
44. MORGANTI S, Tolaney SM
    Fluorouracil and dose-dense adjuvant chemotherapy in breast cancer: lessons learned from the 20-year-old GIM2 trial.
    Lancet Oncol. 2022 Nov 9. pii: S1470-2045(22)00685.
    PubMed    
    
    
    
45. BENARD F, Harsini S, Wilson D, Zukotynski K, et al
    Intra-individual comparison of (18)F-sodium fluoride PET-CT and (99m)Tc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial.
    Lancet Oncol. 2022 Nov 4. pii: S1470-2045(22)00642.
    PubMed     Abstract available
    
    
    October 2022
46. KUERER HM, Smith BD, Krishnamurthy S, Yang WT, et al
    Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2022 Oct 25. pii: S1470-2045(22)00613.
    PubMed     Abstract available
    
    
    
47. VEIGA LHS, Vo JB, Curtis RE, Mille MM, et al
    Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study.
    Lancet Oncol. 2022 Oct 11. pii: S1470-2045(22)00561.
    PubMed     Abstract available
    
    
    
48. RUGO HS, Singer L
    First, do no harm: risk of secondary cancer after breast cancer treatment.
    Lancet Oncol. 2022 Oct 11. pii: S1470-2045(22)00627.
    PubMed    
    
    
    September 2022
49. BIDARD FC, Hardy-Bessard AC, Dalenc F, Bachelot T, et al
    Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
    Lancet Oncol. 2022 Sep 29. pii: S1470-2045(22)00555.
    PubMed     Abstract available
    
    
    August 2022
50. KIROVA Y, Loap P
    Customising radiotherapy in stage II breast cancer after primary chemotherapy.
    Lancet Oncol. 2022 Aug 8. pii: S1470-2045(22)00496.
    PubMed    
    
    
    
51. DE WILD SR, de Munck L, Simons JM, Verloop J, et al
    De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study.
    Lancet Oncol. 2022 Aug 8. pii: S1470-2045(22)00482.
    PubMed     Abstract available
    
    
    
52. HEINDEL W, Weigel S, Hense HW
    Surrogate endpoints in breast cancer screening trials - Authors' reply.
    Lancet Oncol. 2022;23:e361.
    PubMed    
    
    
    
53. JATOI I
    Surrogate endpoints in breast cancer screening trials.
    Lancet Oncol. 2022;23:e360.
    PubMed    
    
    
    July 2022
54. TERAN E, Gomez H, Hannois D, Lema M, et al
    Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective.
    Lancet Oncol. 2022;23:e348-e358.
    PubMed     Abstract available
    
    
    
55. KRISTELEIT R, Oza AM
    Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations - Authors' reply.
    Lancet Oncol. 2022;23:e315.
    PubMed    
    
    
    
56. GANGULY S, Gogia A
    Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations.
    Lancet Oncol. 2022;23:e314.
    PubMed    
    
    
    
57. JOSEPH JP, Bhangdia K, Damuse R, Lormil J, et al
    Impact of geospatial barriers on breast cancer care in Haiti: a retrospective cohort study.
    Lancet Oncol. 2022;23 Suppl 1:S40.
    PubMed     Abstract available
    
    
    
58. VIDAURRE T, Enriquez-Vera D, Bertani S
    Excess mortality in patients with cancer during the COVID-19 pandemic in Peru: an analysis of death registry data.
    Lancet Oncol. 2022;23 Suppl 1:S28.
    PubMed     Abstract available
    
    
    
59. HOMMA MK, Hashimoto Y, Homma Y, Nomizu T, et al
    CK2alpha as a prognostic factor in invasive ductal carcinomas of the breast: cancer recurrence prognosis by surgical sampling.
    Lancet Oncol. 2022;23 Suppl 1:S25.
    PubMed     Abstract available
    
    
    
60. RAMPRASAD J, Krishnan L, Gangadharan C, Deshpande G, et al
    Performance of artificial intelligence-based breast cancer screening in a community setting: a real-world evaluation study.
    Lancet Oncol. 2022;23 Suppl 1:S20.
    PubMed     Abstract available
    
    
    
61. YADAV B, Rana D, Bharti D, Dahiya D, et al
    Impact of COVID-19 pandemic on breast cancer care: report from a regional cancer centre.
    Lancet Oncol. 2022;23 Suppl 1:S17.
    PubMed     Abstract available
    
    
    June 2022
62. HOWELL SJ, Casbard A, Carucci M, Ingarfield K, et al
    Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded bi
    Lancet Oncol. 2022 Jun 1. pii: S1470-2045(22)00284.
    PubMed     Abstract available
    
    
    
63. BRAY F, Parkin DM
    Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs.
    Lancet Oncol. 2022;23:719-728.
    PubMed     Abstract available
    
    
    May 2022
64. FOERSTER M, McCormack V, Anderson BO, Boucheron P, et al
    Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer-Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa: a prospective cohort study.
    Lancet Oncol. 2022 May 9. pii: S1470-2045(22)00198.
    PubMed     Abstract available
    
    
    
65. GOURD E
    Philippa Kibugu-Decuir-founder of Breast Cancer Initiative East Africa.
    Lancet Oncol. 2022 May 9. pii: S1470-2045(22)00249.
    PubMed    
    
    
    
66. YAN M
    Screening for breast cancer brain metastases - Authors' reply.
    Lancet Oncol. 2022;23:e201.
    PubMed    
    
    
    
67. KNISELY J
    Screening for breast cancer brain metastases.
    Lancet Oncol. 2022;23:e200.
    PubMed    
    
    
    April 2022
68. HOUSSAMI N
    Should tomosynthesis replace mammography for breast cancer screening?
    Lancet Oncol. 2022 Apr 12. pii: S1470-2045(22)00215.
    PubMed    
    
    
    
69. HEINDEL W, Weigel S, Gerss J, Hense HW, et al
    Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial.
    Lancet Oncol. 2022 Apr 12. pii: S1470-2045(22)00194.
    PubMed     Abstract available
    
    
    
70. NITZ U, Gluz O, Graeser M, Christgen M, et al
    De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase
    Lancet Oncol. 2022 Apr 8. pii: S1470-2045(22)00159.
    PubMed     Abstract available
    
    
    
71. SAJI S, Taira N, Kitada M, Takano T, et al
    Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
    Lancet Oncol. 2022 Apr 8. pii: S1470-2045(22)00196.
    PubMed     Abstract available
    
    
    
72. QUESADA S, Jacot W
    Maintenance endocrine therapy plus bevacizumab for advanced or metastatic breast cancer.
    Lancet Oncol. 2022 Apr 8. pii: S1470-2045(22)00205.
    PubMed    
    
    
    
73. THIRUCHELVAM PTR, Leff DR, Godden AR, Cleator S, et al
    Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study.
    Lancet Oncol. 2022 Apr 7. pii: S1470-2045(22)00145.
    PubMed     Abstract available
    
    
    March 2022
74. BECERRA-CHAUCA N, Nieto-Gutierrez W, Taype-Rondan A
    6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting.
    Lancet Oncol. 2022;23:e100.
    PubMed    
    
    
    
75. DROUIN E, Classe JM, Hautecoeur P
    Sentinel nodes and breast cancer: an old story.
    Lancet Oncol. 2022;23:340.
    PubMed    
    
    
    
76. ANTONARELLI G, Valenza C, Mayer EL, Loibl S, et al
    Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?
    Lancet Oncol. 2022;23:325-328.
    PubMed    
    
    
    February 2022
77. TRIUNFOL M
    IAEA and Brazilian Navy to provide new arsenal to fight breast cancer: mammography on a ship.
    Lancet Oncol. 2022 Feb 17. pii: S1470-2045(22)00093.
    PubMed    
    
    
    
78. 
    Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.
    Lancet Oncol. 2022 Feb 3. pii: S1470-2045(21)00758.
    PubMed     Abstract available
    
    
    
79. FEYAERTS A, Demey W
    Bone marrow invasion in breast carcinoma.
    Lancet Oncol. 2022;23:e88.
    PubMed    
    
    
    
80. DEVI S
    MSF breast and cervical cancer screening programmes in Mali and Malawi.
    Lancet Oncol. 2022;23:207-208.
    PubMed    
    
    
    January 2022
81. YAN M, Ouyang Q, Sun T, Niu L, et al
    Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial.
    Lancet Oncol. 2022 Jan 24. pii: S1470-2045(21)00716.
    PubMed     Abstract available
    
    
    
82. BAILLEUX C, Bachelot T
    Medical treatment for active breast cancer brain metastases.
    Lancet Oncol. 2022 Jan 24. pii: S1470-2045(22)00022.
    PubMed    
    
    
    
83. FOWLER AM, Strigel RM
    Clinical advances in PET-MRI for breast cancer.
    Lancet Oncol. 2022;23:e32-e43.
    PubMed     Abstract available
    
    
    
84. MEATTINI I, Becherini C, Boersma L, Kaidar-Person O, et al
    European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer.
    Lancet Oncol. 2022;23:e21-e31.
    PubMed     Abstract available
    
    
    December 2021
85. REEVES C
    San Antonio Breast Cancer Symposium 2021.
    Lancet Oncol. 2021 Dec 16. pii: S1470-2045(21)00727.
    PubMed    
    
    
    
86. YAU C, Osdoit M, van der Noordaa M, Shad S, et al
    Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
    Lancet Oncol. 2021 Dec 10. pii: S1470-2045(21)00589.
    PubMed     Abstract available
    
    
    November 2021
87. XIE Y, Mata DGMM, Huang WY, Djordjevic B, et al
    A growing vulvar mass in a post-menopausal woman.
    Lancet Oncol. 2021;22:e530.
    PubMed    
    
    
    October 2021
88. GAO JJ, Cheng J, Prowell TM, Bloomquist E, et al
    Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
    Lancet Oncol. 2021 Oct 14. pii: S1470-2045(21)00472.
    PubMed     Abstract available
    
    
    
89. HEER E
    Addressing breast cancer mortality in low-income and middle-income countries: if you can't measure it, it doesn't exist.
    Lancet Oncol. 2021 Oct 12. pii: S1470-2045(21)00519.
    PubMed    
    
    
    
90. DUGGAN C, Trapani D, Ilbawi AM, Fidarova E, et al
    National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis.
    Lancet Oncol. 2021 Oct 12. pii: S1470-2045(21)00462.
    PubMed     Abstract available
    
    
    
91. DENKERT C, Nekljudova V, Loibl S
    HER2-low-positive breast cancer from four neoadjuvant clinical trials - Authors' reply.
    Lancet Oncol. 2021;22:e427.
    PubMed    
    
    
    
92. OMAR A, Arafat W
    HER2-low-positive breast cancer from four neoadjuvant clinical trials.
    Lancet Oncol. 2021;22:e426.
    PubMed    
    
    
    
93. MANO MS
    Patient-accessible test reports in times of instant messaging communication: progress or an additional emotional burden?
    Lancet Oncol. 2021;22:1365-1366.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.